Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Graft IL-33 regulates infiltrating macrophages to protect against chronic rejection
Tengfang Li, Zhongqiang Zhang, Joe G. Bartolacci, Gaelen K. Dwyer, Quan Liu, Lisa R. Mathews, Murugesan Velayutham, Anna S. Roessing, Yoojin C. Lee, Helong Dai, Sruti Shiva, Martin H. Oberbarnscheidt, Jenna L. Dziki, Steven J. Mullet, Stacy G. Wendell, James D. Wilkinson, Steven A. Webber, Michelle Wood-Trageser, Simon C. Watkins, Anthony J. Demetris, George S. Hussey, Stephen F. Badylak, Hēth R. Turnquist
Tengfang Li, Zhongqiang Zhang, Joe G. Bartolacci, Gaelen K. Dwyer, Quan Liu, Lisa R. Mathews, Murugesan Velayutham, Anna S. Roessing, Yoojin C. Lee, Helong Dai, Sruti Shiva, Martin H. Oberbarnscheidt, Jenna L. Dziki, Steven J. Mullet, Stacy G. Wendell, James D. Wilkinson, Steven A. Webber, Michelle Wood-Trageser, Simon C. Watkins, Anthony J. Demetris, George S. Hussey, Stephen F. Badylak, Hēth R. Turnquist
View: Text | PDF
Research Article Immunology

Graft IL-33 regulates infiltrating macrophages to protect against chronic rejection

  • Text
  • PDF
Abstract

Alarmins, sequestered self-molecules containing damage-associated molecular patterns, are released during tissue injury to drive innate immune cell proinflammatory responses. Whether endogenous negative regulators controlling early immune responses are also released at the site of injury is poorly understood. Herein, we establish that the stromal cell–derived alarmin interleukin 33 (IL-33) is a local factor that directly restricts the proinflammatory capacity of graft-infiltrating macrophages early after transplantation. By assessing heart transplant recipient samples and using a mouse heart transplant model, we establish that IL-33 is upregulated in allografts to limit chronic rejection. Mouse cardiac transplants lacking IL-33 displayed dramatically accelerated vascular occlusion and subsequent fibrosis, which was not due to altered systemic immune responses. Instead, a lack of graft IL-33 caused local augmentation of proinflammatory iNOS+ macrophages that accelerated graft loss. IL-33 facilitated a metabolic program in macrophages associated with reparative and regulatory functions, and local delivery of IL-33 prevented the chronic rejection of IL-33–deficient cardiac transplants. Therefore, IL-33 represents what we believe is a novel regulatory alarmin in transplantation that limits chronic rejection by restraining the local activation of proinflammatory macrophages. The local delivery of IL-33 in extracellular matrix–based materials may be a promising biologic for chronic rejection prophylaxis.

Authors

Tengfang Li, Zhongqiang Zhang, Joe G. Bartolacci, Gaelen K. Dwyer, Quan Liu, Lisa R. Mathews, Murugesan Velayutham, Anna S. Roessing, Yoojin C. Lee, Helong Dai, Sruti Shiva, Martin H. Oberbarnscheidt, Jenna L. Dziki, Steven J. Mullet, Stacy G. Wendell, James D. Wilkinson, Steven A. Webber, Michelle Wood-Trageser, Simon C. Watkins, Anthony J. Demetris, George S. Hussey, Stephen F. Badylak, Hēth R. Turnquist

×

Figure 6

IL-33 targets intragraft myeloid cells to prevent rejection by upregulating their fatty acid uptake and limiting the generation of iNOS+ proinflammatory macrophages.

Options: View larger image (or click on image) Download as PowerPoint
IL-33 targets intragraft myeloid cells to prevent rejection by upregulat...
(A) Il33+/+ or Il33–/– Bm12 grafts were transplanted into WT B6 recipients (n = 5/group). On POD 3, graft-infiltrating leukocyte fatty acid uptake was assessed using flow cytometry with BODIPY. (B) BODIPY uptake for Q2 (CD45+CD11b+CD11c–F4/80+Ly6Chi) and Q3 (CD45+CD11b+CD11c–F4/80+Ly6Clo) populations. Graphs are individual values and group mean ± SD. (C–E) Il33+/+ Bm12 grafts were transplanted into B6 LysMCre or LysMCre × St2fl/fl recipients. On POD 3, graft-infiltrating leukocytes were assessed by flow cytometry. (C) t-Distributed stochastic neighbor embedding (t-SNE) contour plots generated from CD45+CD3–B220–CD11b+-gated cells (n = 3 mice/plot). Population frequency (monoDCs, P1, and P2) for each mouse from C in t-SNE plot. (D) Mean fluorescence intensity (MFI) for F4/80, CD11c, MHCII, and iNOS for monoDC, proinflammatory (P1), and alternatively activated macrophage (P2) populations. (E) Comparison of MFI for CD206 and iNOS staining between P1 and P2 populations from Il33+/+ Bm12 grafts transplanted into B6 LysMCre (white) or LysMCre × St2fl/fl (gray) recipients. Data are from 1 of 2 experiments completed. (F) BODIPY uptake by indicated populations of graft-infiltrating cells in B6 LysMCre (white) or LysMCre × St2fl/fl (gray) recipients. Graphs depict individual values and group mean ± SD for CD45+CD3–B220–CD11b+ P1 and P2 gated cells. (G) Survival of Il33+/+ Bm12 grafts transplanted into B6 LysMCre (white) or LysMCre × St2fl/fl recipients (n = 5–6/group). *P < 0.05; **P < 0.01; ***P < 0.005; ****P < 0.0001 by 2-tailed Student’s t test (B), 1-way ANOVA (C–E), or Kaplan-Meier analysis (G).

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts